Register
Login:
Share:
Email Facebook Twitter




Vernalis Share Price (VER)



Share Price Information for Vernalis (VER)


Share Price: 49.75Bid: 49.00Ask: 50.50Change: -0.25 (-0.50%)Faller - Vernalis
Spread: 1.50Spread as %: 3.06%Open: 49.75High: 49.75Low: 49.75Yesterday’s Close: 50.00

Vernalis Plc Ord 1P

Vernalis is listed in the FTSE AIM 100, FTSE AIM All-Share
Vernalis is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
49.75

Share Price SpacerBid
49.00

Share Price SpacerAsk
50.50

Share Price SpacerChange
-0.50%-0.25

Share Price SpacerVolume
748,784

Share Price SpacerOpen
49.75

Share Price SpacerHigh
49.75

Share Price SpacerLow
49.75

Share Price SpacerClose
50.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 445.13m £226.46m 10,000

52 Week High 87.25 52 Week High Date 10-SEP-2015
52 Week Low 49.00 52 Week Low Date 17-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
12 6,609 742,175 -35.536 -1.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

29-Apr-16
16:44:20
49.75
693,132
 
49.00
50.50
344.83k
Trade Type:
Ordinary
Bargain conditions apply

29-Apr-16
16:17:19
50.00
10,000
Buy* 
49.25
50.50
5,000
Trade Type:
Ordinary

29-Apr-16
15:53:23
50.1425
20,000
Buy* 
49.25
51.00
10.03k
Trade Type:
Ordinary



Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

29-Apr-16
16:44:20
49.75
693,132
unknown 
49.00
50.50
344.83k
Trade Type:
Ordinary
Bargain conditions apply

29-Apr-16
15:53:23
50.1425
20,000
Buy* 
49.25
51.00
10.03k
Trade Type:
Ordinary

29-Apr-16
16:17:19
50.00
10,000
Buy* 
49.25
50.50
5,000
Trade Type:
Ordinary

29-Apr-16
10:40:15
50.17
9,946
Buy* 
49.25
51.00
4,990
Trade Type:
Ordinary

29-Apr-16
14:59:41
49.80
6,476
Sell* 
49.25
51.00
3,225
Trade Type:
Ordinary



View more Vernalis trades >>

Directors Deals for Vernalis (VER)
Trade DateActionNotifierPriceCurrencyAmountHolding
15-Oct-15Exercise of option
Trade Notifier Information for Vernalis
David Mackney held the position of CFO at Vernalis at the time of this trade.
 David Mackney
19.6GBX45,918365203
08-Oct-15Exercise of option
Trade Notifier Information for Vernalis
Ian Garland held the position of CEO at Vernalis at the time of this trade.
 Ian Garland
19.6GBX45,918704857
05-May-15Buy
Trade Notifier Information for Vernalis
Nigel Sheail held the position of Non-Executive Director at Vernalis at the time of this trade.
 Nigel Sheail
59.9GBX84,000294000
View more Vernalis directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Thu 14:26ThomasTheTankEdison note - Research Tree49.75No Opinion
Read Edison's note on VERNALIS, out this morning, by visiting https://www.research-tree.com/company/GB00B3Y5L754
"Vernalis intends to raise £40m (gross) through the issue of 80m new shares at 50p per share. This equity raise will remove any uncertainty over whether Vernalis’s cash position is sufficient to take it through to sustainable profitability in FY18 (on our current forecasts). New funds will be used to boost existing working capital required for a conservative Tuzistra… Read More
6 Apr '16ThomasTheTankEdison note - Research Tree51.50No Opinion
Read Edison’s note on Vernalis (VER), out this morning, by visiting www.research-tree.com
“Vernalis reported a modest £0.6m in Tuzistra XR sales over the first four months post-launch due to the mild cough cold season. The US launch of this prescription-only (Rx), extended release (ER) cough cold medicine is the first step in Vernalis’s transition into a commercial-stage speciality pharma company, targeting a $3.5bn market opportunity. The emphasis for year one… Read More
29 Mar '16hopespringsOver 50% owned by Woodford/ Invesco53.25Strong Buy
92% of Vernalis is owned by institutional investors with Woodford and Invesco owning over 50%
between them.
Vernalis has significant products to help with migraine and even the common cold.These are at advanced
stages of development in America.
The future revenue stream will be in US dollars.Broker targets are over 91p.
Be happy
23 Mar '16KotwariRE: heading towrds 20p range again?54.00No Opinion
Vernalis Shares will catch up again and by the time final Results 27/9,
21 Mar '16estar98heading towrds 20p range again?52.00No Opinion
comparing minnow Sar rising 22%, the share price of VER is still falling, anyone reckon this will touch the 20s range back in 2104? What's the real reason of the falling share price, is it the huge sales cost and the very moderate revenue income reported in the half yearly results?
6 Jan '16PazuzuRNS out70.00No Opinion
6 January 2016
LSE: VER

Vernalis Announces Corvus Pharmaceuticals, Inc. as its Worldwide Licensee for their Adenosine Antagonist Program

Adenosine antagonists under development for use in immuno-oncology

Vernalis plc ("Vernalis" or the "Company") today announces Corvus Pharmaceuticals, Inc. ("Corvus") as its licensee for their adenosine antagonist program.

In February 2015, the Company licensed exclusive, worldwide rights in its adenosine… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Vernalis (VER) >>

Please login or register to post a message on Share Chat.



Vernalis Plc Ord 1P home pageWebsite: Vernalis Plc Ord 1P
Website Description: Vernalis corporate website



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.